Opus Point Partners Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Opus Point Partners Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,588	Closed	-$255K	–	65
2017 Q4	$255K	Sell	5,588 -9,132	-62%	-$456K	0.22%	53
2017 Q3	$660K	Sell	14,720 -3,250	-18%	-$111K	0.59%	38
2017 Q2	$537K	Sell	17,970 -60	-0.3%	-$1.48K	0.49%	43
2017 Q1	$400K	Buy	18,030 +6,552	+57%	+$141K	0.3%	48
2016 Q4	$216K	Buy	11,478 +4,560	+66%	+$112K	0.17%	56
2016 Q3	$208K	Buy	+6,918	New	+$215K	0.12%	45
2015 Q3	–	Sell	-5,000	Closed	-$267K	–	63
2015 Q2	$267K	Buy	+5,000	New	+$265K	0.21%	54

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Opus Point Partners Management's JUNO Position: Q1 2018 in Review

Opus Point Partners Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 5,588 shares — an estimated $255K sold.

Opus Point Partners Management first reported a position in JUNO in Q2 2015 and held it in 7 quarters. The position peaked at $660K in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Opus Point Partners Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Opus Point Partners Management sold 5,588 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $255K.
Opus Point Partners Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 7 quarters.
Opus Point Partners Management's Juno Therapeutics, Inc. position peaked at $660K in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Opus Point Partners Management's 13F filing for Q1 2018, filed 15 May 2018.